ArticleGenes & genomics2021
MiR-137 inhibits the proliferation, invasion and migration of glioma via targeting to regulate EZH2.
Article in Genes & genomics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 10 citations in OpenAlex.
- Enhancer of Zeste Homolog 2 (EZH2): From Glioblastoma Biology to Potential Epigenetic Therapy.International journal of molecular sciences · 2026Review
- Epigenetic regulation of histone modifications in glioblastoma: recent advances and therapeutic insights.Biomarker research · 2025Review
- First-in-Class Dual EZH2-HSP90 Inhibitor Eliciting Striking Antiglioblastoma ActivityJournal of medicinal chemistry · 2024Article
- The Role of Non-Coding RNAs in Epigenetic Dysregulation in Glioblastoma Development.International journal of molecular sciences · 2023Review
- CAMK1D Inhibits Glioma Through the PI3K/AKT/mTOR Signaling Pathway.Frontiers in oncology · 2022Article
- Procollagen C-protease enhancer protein is a prognostic factor for glioma and promotes glioma development by regulating multiple tumor-related pathways and immune microenvironment.International journal of immunopathology and pharmacologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGliomas are common malignant tumors in the nervous system, known for poor prognosis and low survival rate.
objectiveThis study aims to explore functions of miR-137 in glioma progression and identify messenger RNAs (mRNA) regulated by miR-137, which provides new ideas for further exploration of glioma therapeutic targets.
methodsGene expression data were downloaded from the Cancer Genome Atlas database, and abnormally expressed miRNAs and mRNAs in glioma were analyzed. The expression of genes in 20 pairs of clinical tissue samples and glioma cell lines were detected through qRT-PCR, and the expression of proteins was detected through Western blot. Changes in cell proliferative level after transfection were detected via CCK8 assay, and changes in cell migratory and invasive abilities were detected by Transwell assay. Besides, dual-luciferase reporter assay was employed to testify binding relationship between two genes.
resultsOur study found that miR-137 was significantly and lowly expressed in glioma tissue and cell lines, and the prognoses of glioma patients with highly expressed miR-137 were more optimistic. Overexpressed miR-137 could remarkably inhibit proliferative, invasive and migratory abilities of glioma cells U87, while transfection of miR-137 inhibitor presented an opposite effect. Additionally, EZH2 was a direct target of miR-137 and overexpressed EZH2 effectively reversed the effect of miR-137 on glioma proliferation and migration.
conclusionsOur study found that miR-137 could suppress the proliferation, invasion and migration of glioma cells through regulating the expression of EZH2. So far, we have found a novel regulatory pair that influences glioma progression, providing a basis for further development of new therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.